Latest Neuroimaging News

Page 2 of 2

Alterity’s ATH434 Slows Progression in Advanced Multiple System Atrophy

Alterity Therapeutics has reported encouraging topline results from its open-label Phase 2 trial of ATH434 in advanced Multiple System Atrophy, showing slowed disease progression and biomarker stabilization.

Ada Torres

28 July 2025

Browse the archive

Full archive

Oct 2026 Sept 2026 Aug 2026 July 2026 June 2026 May 2026 Apr 2026 Mar 2026

Top